ixekizumab vs vunakizumab

NCT01695239 · Phase 3 · completed

This randomized, quadruple-blind, placebo- and active-comparator-controlled trial in 417 people with active psoriatic arthritis measured ACR20 response at week 24 as its primary endpoint. Both ixekizumab doses clearly outperformed placebo (57.9% and 62.1% vs 30.2%, p<0.001), and the active comparator adalimumab also beat placebo, confirming the trial could detect a true effect.

NCT05055934 · Phase 2 · completed

The study was randomized, quadruple-blind, placebo-controlled, and included 112 participants, using the clinical ACR20 improvement measure as its primary endpoint. Because the registry does not report whether the primary endpoint was met, the trial provides well-designed but currently incomplete evidence.

NCT01474512 · Phase 3 · completed

The study was randomized, quadruple-blind, placebo-controlled, and included 1,296 participants. Its clinical primary endpoints, sPGA 0/1 and PASI75 at Week 12, were met for both ixekizumab regimens versus placebo, with p<0.001 for each comparison.

NCT04839016 · Phase 3 · status unknown

This randomised, double-blind, placebo-controlled trial in 660 patients with moderate-to-severe plaque psoriasis reported PASI 90 in 76.8% of patients on vunakizumab against 0.9% on placebo at week 12, with sPGA 0/1 in 71.8% against 0.4%, both standard measures of skin clearance.